NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
NKGen Biotech (OTC: NKGN) announced an upcoming presentation of Phase 1 clinical data for troculeucel, their cryopreserved expanded autologous NK cell therapy for moderate Alzheimer's disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. The presentation, titled "Use of Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Patients with Alzheimer's Disease. Preliminary Clinical and Biomarker Results," will be delivered by Dr. Paul Y. Song on May 14, 2025, at 2:30 PM CT in New Orleans.
NKGen Biotech (OTC: NKGN) ha annunciato una prossima presentazione dei dati clinici di Fase 1 per troculeucel, la loro terapia con cellule NK autologhe espanse e crioconservate per il trattamento dell'Alzheimer moderato (AD), al 28° Congresso Annuale della American Society of Gene and Cell Therapy (ASGCT). La presentazione, intitolata "Uso di cellule Natural Killer espanse non geneticamente modificate (Troculeucel) con citotossicità potenziata in pazienti con malattia di Alzheimer. Risultati preliminari clinici e di biomarcatori," sarà tenuta dal Dr. Paul Y. Song il 14 maggio 2025 alle 14:30 CT a New Orleans.
NKGen Biotech (OTC: NKGN) anunció una próxima presentación de datos clínicos de Fase 1 para troculeucel, su terapia con células NK autólogas expandidas y criopreservadas para la enfermedad de Alzheimer moderada (AD), en la 28ª Reunión Anual de la American Society of Gene and Cell Therapy (ASGCT). La presentación, titulada "Uso de células Natural Killer expandidas no modificadas genéticamente (Troculeucel) con citotoxicidad mejorada en pacientes con enfermedad de Alzheimer. Resultados preliminares clínicos y de biomarcadores," será impartida por el Dr. Paul Y. Song el 14 de mayo de 2025 a las 2:30 PM CT en Nueva Orleans.
NKGen Biotech (OTC: NKGN)는 중등도 알츠하이머병(AD) 치료를 위한 냉동 보존된 자가 확장 자연 살해 세포 치료제 troculeucel의 1상 임상 데이터 발표를 미국 유전자 및 세포 치료 학회(ASGCT) 제28회 연례 회의에서 진행할 예정이라고 발표했습니다. "알츠하이머병 환자에서 유전자 변형되지 않은 확장 자연 살해 세포(Troculeucel)의 향상된 세포독성 활용: 예비 임상 및 바이오마커 결과"라는 제목의 발표는 2025년 5월 14일 오후 2시 30분 CT에 뉴올리언스에서 Paul Y. Song 박사가 진행할 예정입니다.
NKGen Biotech (OTC : NKGN) a annoncé une prochaine présentation des données cliniques de phase 1 pour troculeucel, leur thérapie par cellules NK autologues expansées cryoconservées pour la maladie d'Alzheimer modérée (MA), lors de la 28e réunion annuelle de l'American Society of Gene and Cell Therapy (ASGCT). La présentation, intitulée « Utilisation de cellules tueuses naturelles non génétiquement modifiées expansées (Troculeucel) avec une cytotoxicité améliorée chez des patients atteints de la maladie d'Alzheimer. Résultats cliniques et biomarqueurs préliminaires », sera donnée par le Dr Paul Y. Song le 14 mai 2025 à 14h30 CT à la Nouvelle-Orléans.
NKGen Biotech (OTC: NKGN) kündigte eine bevorstehende Präsentation von Phase-1-Klinikdaten für troculeucel an, ihre kryokonservierte, expandierte autologe NK-Zelltherapie für mittelschwere Alzheimer-Krankheit (AD), auf dem 28. Jahreskongress der American Society of Gene and Cell Therapy (ASGCT). Die Präsentation mit dem Titel „Einsatz von expandierten, nicht genetisch veränderten natürlichen Killerzellen (Troculeucel) mit verbesserter Zytotoxizität bei Patienten mit Alzheimer-Krankheit. Vorläufige klinische und Biomarker-Ergebnisse“ wird von Dr. Paul Y. Song am 14. Mai 2025 um 14:30 Uhr CT in New Orleans gehalten.
- None.
- None.
SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company’s Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will take place in New Orleans, Louisiana from May 13–17, 2025.
Presentation Details
Title: Use of Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Patients with Alzheimer's Disease. Preliminary Clinical and Biomarker Results.
Presenting Author: Paul Y. Song, M.D.
Session Details: Gene Therapy Clinical Trials - Oral Presentation
Location: NOLA Theater B
Presentation Date & Time: Wednesday, May 14, 2025; 2:30–2:45 PM, Central Time
Previously disclosed data for troculeucel in Alzheimer’s disease and solid tumors can be found on the Company’s website at https://nkgenbiotech.com/scientific-publications/. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company’s website at https://nkgenbiotech.com/news/.
About Troculeucel
Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
External Contact:
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
What will NKGen Biotech present at the ASGCT 2025 Annual Meeting?
When and where will NKGN present their Alzheimer's disease trial results?
What is troculeucel and what is it being developed for by NKGen Biotech?
Who will present NKGen Biotech's clinical data at ASGCT 2025?
